You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ATG-010

Showing 1 - 25 of 334
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed/Refractory Diffuse Large B-cell Lymphoma Trial in China (ATG-010 and ATG-008)

Recruiting
  • Relapsed/Refractory Diffuse Large B-cell Lymphoma
  • ATG-010 and ATG-008
  • Chongqing, Chongqing, China
  • +5 more
Sep 2, 2022

Multiple Myeloma Trial in Zhengzhou, Wuhan, Xi'an (Selinexor (80mg/d), Selinexor (100mg/d), Pegylated liposomal doxorubicin)

Recruiting
  • Multiple Myeloma
  • Selinexor (80mg/d)
  • +4 more
  • Zhengzhou, Henan, China
  • +4 more
Aug 16, 2022

Multiple Myeloma Trial in Guangzhou (Selinexor, Bortezomib, Lenalidomide)

Recruiting
  • Multiple Myeloma
  • Guangzhou, Guangdong, China
  • +3 more
Aug 16, 2022

Relapse/Refractory Multiple Myeloma Trial in China (ATG-010)

Completed
  • Relapse/Refractory Multiple Myeloma
  • ATG-010
  • Beijing, Beijing, China
  • +16 more
Jul 27, 2022

CNS Lymphoma Trial in China (Selinexor, Rituximab, Methotrexate)

Not yet recruiting
  • Central Nervous System Lymphoma
  • Hefei, Anhui, China
  • +4 more
Jan 26, 2023

1. Relapsed Ovarian Cancer 2. Metastatic Ovarian Cancer 3. Endometrial Cancer 4. Cervical Cancer Trial in Chongqing (ATG-008,

Not yet recruiting
  • 1. Relapsed Ovarian Cancer 2. Metastatic Ovarian Cancer 3. Endometrial Cancer 4. Cervical Cancer
  • Chongqing, Chongqing, China
    Chongqing Cancer Hospital
Aug 4, 2021

DLBCL Germinal Center B-Cell Type Trial in China (Selinexor, Rituximab, Cyclophosphamide)

Recruiting
  • DLBCL Germinal Center B-Cell Type
  • Guangzhou, Guangdong, China
  • +5 more
Aug 16, 2022

Multiple Myeloma Trial in Shanghai (Selinexor, Thalidomide, Lenalidomide)

Recruiting
  • Multiple Myeloma
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Mar 3, 2022

Relapsed/Refractory DLBCL (DLBCL) Trial in China (ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle)

Recruiting
  • Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
  • ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle
  • Beijing, Beijing, China
  • +14 more
Jul 19, 2021

Multiple Myeloma Trial in Chengdu (Selinexor, Thalidomide, Dexamethasone)

Not yet recruiting
  • Multiple Myeloma
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
May 13, 2021

Recurrent Histiocytic and Dendritic Cell Tumor, Recurrent Non-Hodgkin Lymphoma, Refractory Histiocytic and Dendritic Cell Tumor

Recruiting
  • Recurrent Histiocytic and Dendritic Cell Neoplasm
  • +3 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Dec 5, 2022

Relapsed or Refractory Multiple Myeloma Trial in China (SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone))

Recruiting
  • Relapsed or Refractory Multiple Myeloma
  • SVd (Selinexor+Bortezomib+dexamethasone)
  • Vd (Bortezomib+dexamethasone)
  • Hefei, Anhui, China
  • +33 more
Aug 14, 2022

Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma Trial in Sacramento

Recruiting
  • Advanced Urothelial Carcinoma
  • +3 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Jun 28, 2022

MGMT-Methylated Glioblastoma, Recurrent Glioblastoma, IDH-Wildtype Trial (Selinexor, Temozolomide)

Not yet recruiting
  • MGMT-Methylated Glioblastoma
  • Recurrent Glioblastoma, IDH-Wildtype
  • (no location specified)
Jun 28, 2022

Advanced Alveolar Soft Part Sarcoma, Advanced Soft Tissue Sarcoma, Metastatic Alveolar Soft Part Sarcoma Trial run by the NCI

Recruiting
  • Advanced Alveolar Soft Part Sarcoma
  • +3 more
  • Atezolizumab
  • +5 more
  • Bethesda, Maryland
  • +1 more
Jan 28, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (Carfilzomib, Dexamethasone, Pomalidomide)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jun 3, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in United States (drug, biological, other)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Des Moines, Iowa
  • +8 more
Jan 12, 2023

Advanced Malignant Solid Tumor, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +28 more
  • Conroe, Texas
  • +4 more
Dec 5, 2022

Aplastic Anemia Trial in Beijing (Ciclosporin, Avatrombopag, Anti-Human Thymocyte Immunoglobulin, Rabbit)

Not yet recruiting
  • Aplastic Anemia
  • Beijing, China
    Peking union medical college hospital
Aug 16, 2023

Aplastic Anemia, CSA, Drug Therapy Trial in Beijing (CsA+ATG+Herombopag, CsA+Herombopag)

Recruiting
  • Aplastic Anemia
  • +2 more
  • Beijing, China
    Peking union medical college hospital
Aug 20, 2023

Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified, Diffuse Intrinsic Pontine Glioma Trial in United States

Recruiting
  • Anaplastic Astrocytoma
  • +6 more
  • Biopsy
  • +3 more
  • Birmingham, Alabama
  • +62 more
Feb 2, 2023

Hematological Malignancies Trial in Belgium, Netherlands (Conditioning regimen: TBI + Fludarabine, Conditioning regimen:TLI (8

Completed
Has Results
  • Hematological Malignancies
  • Conditioning regimen: TBI + Fludarabine
  • Conditioning regimen:TLI (8 Gy) + ATG
  • Leuven, Flamish Brabant, Belgium
  • +10 more
Nov 16, 2021

Advanced Solid Tumors, B-cell Non-Hodgkin Lymphomas Trial (ATG-031)

Not yet recruiting
  • Advanced Solid Tumors
  • B-cell Non-Hodgkin Lymphomas
  • (no location specified)
Aug 31, 2023

Advanced NSCLC Trial in Shanghai (GLS-012+GLS-010, GLS-012+GLS-010+pemetrexed+carboplatin,

Not yet recruiting
  • Advanced Non-Small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shang Hai Pulmonary Hospital
Aug 3, 2023

Locally Advanced Pancreatic Cancer Trial (Stereotactic body radiation(SBRT), Zimberelimab (GLS-010))

Not yet recruiting
  • Locally Advanced Pancreatic Cancer
  • Stereotactic body radiation(SBRT)
  • Zimberelimab (GLS-010)
  • (no location specified)
Aug 22, 2023